Alnylam Pharmaceuticals said this week that the US Patent and Trademark Office has allowed a patent application covering compositions and methods for siRNAs.
The application, No. 20070275465, is entitled, "Double-Stranded Ribonucleic Acid with Increased Effectiveness in an Organism." According to Alnylam, claims in the application include a dsRNA of any length having effectiveness in inhibiting a target gene via RNAi; overhang or blunt-end design features; and a 19 to 28 nucleotide region of the antisense strand that is complementary to a target gene.
The company acquired the intellectual property through its purchase of Germany's Ribopharma in 2003.